tipifarnib has been researched along with Neuroblastoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Liu, X; Schell, T; Spiegelman, VS; Sundstrom, JM; Wang, HG; Wills, CA; Young, MM; Zhang, J; Zhao, Y; Zhou, M | 1 |
1 other study(ies) available for tipifarnib and Neuroblastoma
| Article | Year |
|---|---|
Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Extracellular Vesicles; Humans; Immunologic Factors; Immunotherapy; Mice; Neuroblastoma; Quinolones; Tumor Microenvironment | 2022 |